EcoDrugPlus

Notch Receptor 1b

Ensembl ID : ENSIPUG00000014744
Gene Symbol: NOTCH1B
4 Cross references
201 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSIPUG00000005680
Gene Symbol: NOTCH3
4 Cross references
199 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSIPUG00000016031
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSIPUG00000019883
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSIPUG00000017144
Gene Symbol: LOC108264843
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSIPUG00000010081
Gene Symbol: NR3C1
4 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSIPUG00000004309
Gene Symbol: NR3C2
3 Cross references
211 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSIPUG00000016211
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSIPUG00000010202
Gene Symbol: OPRL1
3 Cross references
189 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSIPUG00000010763
Gene Symbol: OPRD1
3 Cross references
192 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSIPUG00000016161
Gene Symbol: OPRK1
3 Cross references
198 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSIPUG00000016639
Gene Symbol: OPRD1B
3 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).